AmVac AG Granted Patent for new Vaccine Development

ZUG, Switzerland, April 1, 2010 – The Swiss company AmVac AG, a biopharmaceutical company
located in Zug, has been granted a European patent (EP 1851 239 B1) for its
Sendai platform technology for its subsidiary company AmVac Research GmbH.
Thus, the novel technology for producing vaccines that has been developed at
the research site in Martinsried near Munich, [...]